塞利西克利布:一种新的治疗方法 库辛病?
Eleni Armeni1, Ashley Grossman1,2,3
1Department of Endocrinology and NET Unit, Royal Free Hospital, London, UK.
TouchREVIEWS in endocrinology
|May 30, 2024
概括
塞利西克利布可以通过抑制皮质瘤瘤生长来治疗库辛病. 这种向垂体的药物影响细胞增殖和分泌,提供潜在的治疗益处.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 皮质瘤经常过度表达环素E.
- 循环E依赖性激酶调节细胞的增殖和分泌.
- 抑制这些激酶可能为垂体瘤提供治疗效果.
研究的目的:
- 为了研究塞利西克利布 (R-roscovitine) 在库辛病中的治疗潜力.
- 评估塞利西克利布对库辛病患者生化参数的影响.
- 评估Seliciclib在调节皮质型瘤细胞通路中的作用.
主要方法:
- 一项涉及小组库辛病患者的研究.
- 用Seliciclib来评估其对生物化学标记物的影响.
- 对环林E和视网膜母细胞瘤蛋白介导通路的分析.
主要成果:
- 塞利西克利布在调节库辛病患者的生物化学参数方面表现出潜力.
- 初步数据表明,赛利西克利布可以抑制皮质型瘤细胞的生长.
- 该药物通过环林E和视网母细胞瘤蛋白通路起作用.
结论:
- 塞利西克利布作为治疗库辛病的治疗剂显示出希望.
- 需要进一步的研究来证实seliciclib的疗效和安全性.
- 准细胞循环通路为治疗垂体瘤提供了一种新的方法.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
157
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
157
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
Drugs for Treatment of Diarrhea-Predominant IBS
159
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
159
Oral Hypoglycemic Agents: Sulfonylureas
205
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
205
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
445
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
445
Peptic Ulcer Disease IV: Management
87
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
87


